{
  "abstract": "Background: Therapeutic options for hyperuricemia (HUA) and its complications remain inadequate, particularly when gouty arthritis (GA) and hyperuricemic nephropathy (HN) coexist. Agents with combined urate-lowering, anti-inflammatory, and renoprotective effects are therefore needed. Evodiamine (EVO), a major alkaloid from Evodia rutaecarpa , exhibits anti-inflammatory and analgesic activities, but its role in HUA-related disorders has not been fully defined.\n\nStudy design and methods: We examined the effects of Evodia rutaecarpa water extract (ERWE) and EVO in experimental models of HUA, HN, and GA.\n\nResults: In the HUA model, ERWE reduced plasma UA levels and increased urinary UA concentration, accompanied by reductions in ALT, AST, and selected inflammatory measurements. Metabolomic profiling indicated that these effects were associated with alterations in pyrimidine metabolism, α-linolenic acid metabolism, and butyrate-related pathways. In the HN model, EVO lowered serum UA and creatinine levels, improved renal pathology, and reduced renal URAT1 and GLUT9 expression. EVO also suppressed NLRP3/caspase-1/IL-1β signaling and reduced the expression of fibrosis-related markers, including α-SMA, COL1A1, and TIMP1. In the GA model, EVO alleviated monosodium urate (MSU)-induced ankle swelling, leukocyte infiltration, and inflammatory mediator production, including IL-1β, TNF-α, and MPO, while inhibiting NLRP3 inflammasome activation.\n\nConclusion: ERWE and the alkaloid EVO showed significant protective effects in experimental HUA-related disorders. EVO, in particular, exerted urate-lowering, renoprotective, and anti-inflammatory activities, possibly through regulation of urate transporters and NLRP3 inflammasome signaling.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hematology, Hospital of Chengdu University of Traditional Chinese Medicine",
    "Department of Nephrology, the Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University)",
    "Department of Laboratory Medicine, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou Key Laboratory for In Vitro Diagnosis of Hypertensive Disorders of Pregnancy",
    "Department of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine",
    "Sichuan Academy of Chinese Medicine Sciences",
    "TCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yu Mou"
    },
    {
      "affs": [
        1
      ],
      "name": "Wenhao Liao"
    },
    {
      "affs": [
        0
      ],
      "name": "Qun Niu"
    },
    {
      "affs": [
        0
      ],
      "name": "Xue Zhan"
    },
    {
      "affs": [
        2
      ],
      "name": "Tianxin Zhang"
    },
    {
      "affs": [
        3
      ],
      "name": "YuChen Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Hong Che"
    },
    {
      "affs": [
        0
      ],
      "name": "Peijia Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiangdong Yang"
    },
    {
      "affs": [
        4,
        5
      ],
      "name": "Jianyuan Tang"
    },
    {
      "affs": [
        5
      ],
      "name": "Zhilei Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0b2pmd4zg3nq0.bib",
  "cited_by": 0,
  "doi": "10.3389/fimmu.2026.1932250",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13735098/",
  "id": "0b2pmd4zg3nq0",
  "issns": [
    "1664-3224"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1932250/full",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2727|Gout, Hyperuricemia, Uric Acid"
    ]
  ],
  "openalex": "W7223175393",
  "pdf_url": "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1932250/pdf",
  "pmcid": "PMC13735098",
  "pmid": "42990729",
  "published": "2026-10-22",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/0b2pmd4zg3nq0.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:17Z",
      "native_id": "10.3389/fimmu.2026.1932250",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1932250/full"
    },
    {
      "first_seen": "2026-11-09T12:20:52Z",
      "native_id": "PMC13735098",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fimmu.2026.1932250"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "issn:1664-3224",
      "subfield": "immunology"
    }
  ],
  "title": "Evodiamine attenuates hyperuricemia-associated gouty arthritis and renal injury through urate-inflammatory axis modulation",
  "title_text": "Evodiamine attenuates hyperuricemia-associated gouty arthritis and renal injury through urate-inflammatory axis modulation",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T12:20:52Z",
  "url": "https://research.draconitic.com/paper/0b2pmd4zg3nq0",
  "venue": "Frontiers in Immunology",
  "versions": []
}